Guizhou Sanli Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Guizhou Sanli Pharmaceutical Co Ltd working capital to net assets ratio. Guizhou Sanli Pharmaceutical Co Ltd (603439) has a Working Capital to Net Assets ratio of 28.2% as of September 2025. Working capital of CN¥435.86 Million (current assets of CN¥1.41 Billion minus current liabilities of CN¥973.37 Million) is measured against net assets of CN¥1.55 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check how tangible is Guizhou Sanli Pharmaceutical Co Ltd's equity to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
Working capital to net assets ratio of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024. This chart shows how Guizhou Sanli Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 28.2%, reflecting working capital of CN¥435.86 Million against net assets of CN¥1.55 Billion CNY. See 603439 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Guizhou Sanli Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2013–2024)
Guizhou Sanli Pharmaceutical Co Ltd working capital to net assets ratio by year from 2013 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Guizhou Sanli Pharmaceutical Co Ltd balance sheet assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 35.3% | CN¥563.53 Million | CN¥1.59 Billion | CN¥1.80 Billion | CN¥1.23 Billion | ▼ -2.9 pp |
| 2023 | 38.3% | CN¥654.46 Million | CN¥1.71 Billion | CN¥1.49 Billion | CN¥839.01 Million | ▼ -12.1 pp |
| 2022 | 50.3% | CN¥623.38 Million | CN¥1.24 Billion | CN¥1.17 Billion | CN¥548.68 Million | ▼ -21.3 pp |
| 2021 | 71.6% | CN¥739.12 Million | CN¥1.03 Billion | CN¥1.10 Billion | CN¥360.42 Million | ▲ +4.8 pp |
| 2020 | 66.8% | CN¥656.10 Million | CN¥981.88 Million | CN¥920.01 Million | CN¥263.91 Million | ▼ -7.8 pp |
| 2019 | 74.6% | CN¥485.93 Million | CN¥651.09 Million | CN¥552.11 Million | CN¥66.18 Million | ▲ +7.4 pp |
| 2018 | 67.2% | CN¥348.30 Million | CN¥518.02 Million | CN¥395.02 Million | CN¥46.72 Million | ▼ -5.8 pp |
| 2017 | 73.0% | CN¥345.57 Million | CN¥473.36 Million | CN¥425.75 Million | CN¥80.18 Million | ▲ +2.3 pp |
| 2016 | 70.7% | CN¥304.30 Million | CN¥430.59 Million | CN¥380.45 Million | CN¥76.15 Million | ▲ +27.0 pp |
| 2015 | 43.7% | CN¥94.61 Million | CN¥216.53 Million | CN¥174.64 Million | CN¥80.03 Million | ▼ -6.5 pp |
| 2014 | 50.1% | CN¥54.62 Million | CN¥108.92 Million | CN¥194.29 Million | CN¥139.67 Million | ▼ -15.2 pp |
| 2013 | 65.4% | CN¥45.18 Million | CN¥69.09 Million | CN¥175.70 Million | CN¥130.52 Million | — |